Introduction: Aortic stenosis (AS) is a valvular heart disease that obstructs ... followed by a fully connected (FC) layer to output classification results. This structural optimization improves AS ...

Introduction: Transcatheter aortic ... Aortic Stenosis in Patients Who Cannot Undergo Surgery” amassing an impressive 5,400 citations. While, the paper titled “Transcatheter Aortic-Valve Replacement ...

Other heart-related causes can include aortic stenosis, a narrowing of the aortic valve that increases ... High triglycerides (a type of lipid, or fat, in the blood) Low HDL (good) cholesterol High ...

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis By Lori Solomon HealthDay ReporterMONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...

In that trial, among 901 people over age 65 with asymptomatic severe aortic stenosis, low surgical risk, and preserved left ventricular ejection fraction (LVEF), upfront TAVR resulted in fewer ...

In the EARLY TAVR trial, which informed the approval, patients with asymptomatic severe aortic stenosis were randomly assigned to either TAVR or watchful waiting. During a median follow-up of 3.8 ...

Asymptomatic patients with severe aortic stenosis can now undergo transcatheter aortic valve replacement, thanks to the US Food and Drug Administration’s approval of the new indication for the balloon ...

A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis. Edwards Lifesciences’ TAVR platform is the first to be approved in this population.